Inactive Instrument

PT Kalbe Farma Tbk Share Price INDONESIA S.E.

Equities

KLBF

ID1000096803

Pharmaceuticals

End-of-day quote INDONESIA S.E.
- IDR - Intraday chart for PT Kalbe Farma Tbk
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 32,560B 2.05B 170B Sales 2025 * 34,951B 2.2B 183B Capitalization 66,839B 4.21B 349B
Net income 2024 * 3,132B 197M 16.36B Net income 2025 * 3,496B 220M 18.26B EV / Sales 2024 * 1.94 x
Net cash position 2024 * 3,714B 234M 19.4B Net cash position 2025 * 4,587B 289M 23.96B EV / Sales 2025 * 1.78 x
P/E ratio 2024 *
21.4 x
P/E ratio 2025 *
19.2 x
Employees -
Yield 2024 *
2.28%
Yield 2025 *
2.4%
Free-Float 40.44%
More Fundamentals * Assessed data
PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy MT
PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nomura Adjusts Kalbe Farma’s Price Target to IDR2,500 From IDR2,250, Keeps at Buy MT
Progen Co. Ltd. announced that it has received IDR 155.72 billion in funding from PT Kalbe Farma Tbk. CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
PT Kalbe Farma Tbk. completed the acquisition of a 80% stake in PT Aventis Pharma from Hoechst GmbH and Sanofi-Aventis Participations S.A.S. CI
Nomura Adjusts Kalbe Farma's Price Target to 2,250 Rupiahs From 1,905 Rupiahs, Keeps at Buy MT
PT Kalbe Farma Tbk. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
PT Kalbe Farma Tbk. entered into agreement to acquire 80% stake in PT Aventis Pharma from Hoechst GmbH and Sanofi-Aventis Participations S.A.S. CI
PT Kalbe Farma Tbk.'s Equity Buyback announced on February 10, 2022, has expired. CI
More news
Managers TitleAgeSince
Chief Executive Officer 59 01/97/01
Chairman 62 01/97/01
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 59 01/00/01
Chairman 62 01/97/01
Director/Board Member 52 01/15/01
More insiders
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW